News | Brachytherapy Systems, Women's Healthcare | August 30, 2017

Approval finalizes availability of complete suite of Xoft System products in China

China FDA Approves Xoft Axxent Balloon Applicators for Early-Stage Breast Cancer

August 30, 2017 — iCAD Inc. announced that the company’s Xoft Axxent balloon applicators have received approval from the China Food & Drug Administration (CFDA) for the treatment of early-stage breast cancer. The Xoft Axxent balloon applicators are a key component of the Xoft Axxent Electronic Brachytherapy (eBx) System, which is used to perform intraoperative radiation therapy (IORT) in early-stage breast cancer patients who meet specific selection criteria.

With this CFDA approval, the complete suite of Xoft System products is now available to clinicians and patients in China.

IORT with the Xoft System allows radiation oncologists and breast surgeons to work together to deliver a full course of radiation to the tumor site at the time of lumpectomy. The balloon applicator is used to deliver a single, precise dose of radiation to the lumpectomy cavity, directly targeting cancer cells while minimizing exposure to healthy surrounding tissue. In the procedure, the Xoft System’s miniaturized X-ray source is inserted into the balloon applicator, providing a channel to deliver high-dose rate, low-energy radiation treatment. The balloon applicator is available in multiple sizes and shapes, can be filled with different volumes of saline to best fit the contour of the surgical cavity, and allows delivery of a more conformal radiation dose.

“The Xoft Axxent balloon applicators offer an attractive option for physicians and patients who desire improved flexibility, precision and personalization in the targeted treatment of early-stage breast cancer,” said Liu Yu, COO of Chindex Medical Limited, the distributor of iCAD’s Xoft System in China. “We are pleased to continue working with iCAD in offering our customers access to the most advanced cancer treatments, including the complete portfolio of Xoft System products, in the years ahead.”

The Xoft System is U.S. Food and Drug Administration (FDA)-cleared for the treatment of cancer anywhere in the body, including early-stage breast cancer, non-melanoma skin cancer and gynecological cancers.

For more information: www.xoftinc.com

Related Content

News | Radiation Oncology

May 17, 2022 — Radiation oncologists will meet with congressional leaders and staff today to ask for their support of ...

Time May 17, 2022
arrow
Videos | Proton Therapy

John C. Breneman, M.D., medical director of the Cincinnati Children's/UC Health Proton Therapy Center, and the principal ...

Time May 16, 2022
arrow
News | Ultrasound Women's Health

May 16, 2022 — The Barcelona Supercomputing Center (BSC) coordinates QUSTom (Quantitative Ultrasound Stochastic ...

Time May 16, 2022
arrow
News | Breast Imaging

May 16, 2022 — iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy ...

Time May 16, 2022
arrow
News | Women's Health

May 12, 2022 — Volpara Health will showcase new and updated products for its integrated platform for the delivery of ...

Time May 12, 2022
arrow
News | Treatment Planning

May 11, 2022 — Elekta has evolved radiosurgery to an unprecedented level with the launch of Elekta Esprit. This latest ...

Time May 11, 2022
arrow
News | Radiology Education

May 11, 2022 — DetectedX announced that it will launch its Radiology Online Learning Platform to radiologists in the ...

Time May 11, 2022
arrow
News | Treatment Planning

May 10, 2022 — GE Healthcare is proud to announce that it has entered into an agreement to collaborate with RaySearch ...

Time May 10, 2022
arrow
News | Radiation Therapy

May 10, 2022 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on ...

Time May 10, 2022
arrow
News | Radiation Therapy

May 6, 2022 — Accuray Incorporated announced that its ClearRT helical fan-beam kVCT imaging capability for the Radixact ...

Time May 06, 2022
arrow
Subscribe Now